Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $51.77 in the prior trading day, Akero Therapeutics Inc (NASDAQ: AKRO) closed at $51.52, down -0.48%. In other words, the price has decreased by -$0.48 from its previous closing price. On the day, 0.8 million shares were traded. AKRO stock price reached its highest trading level at $52.73 during the session, while it also had its lowest trading level at $50.57.
Ratios:
Our goal is to gain a better understanding of AKRO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.80 and its Current Ratio is at 16.80. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on January 30, 2025, Upgraded its rating to Buy and sets its target price to $63 from $35 previously.
On January 27, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $50 to $72.
On November 18, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $65.Citigroup initiated its Buy rating on November 18, 2024, with a $65 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 07 ’25 when Timothy Rolph bought 56,250 shares for $51.85 per share.
Lamy Patrick sold 2,000 shares of AKRO for $105,760 on Jul 01 ’25. The Senior VP, Commercial Strategy now owns 29,891 shares after completing the transaction at $52.88 per share. On Jul 01 ’25, another insider, PATRICK D LAMY, who serves as the Officer of the company, bought 2,000 shares for $53.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 4107050752 and an Enterprise Value of 3603661568.
Stock Price History:
The Beta on a monthly basis for AKRO is -0.27, which has changed by 1.2487996 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, AKRO has reached a high of $58.40, while it has fallen to a 52-week low of $21.02. The 50-Day Moving Average of the stock is 6.35%, while the 200-Day Moving Average is calculated to be 32.35%.
Shares Statistics:
The stock has traded on average 1.66M shares per day over the past 3-months and 1803480 shares per day over the last 10 days, according to various share statistics. A total of 79.67M shares are outstanding, with a floating share count of 71.75M. Insiders hold about 9.99% of the company’s shares, while institutions hold 101.97% stake in the company. Shares short for AKRO as of 1749772800 were 7751439 with a Short Ratio of 4.66, compared to 1747267200 on 6297082. Therefore, it implies a Short% of Shares Outstanding of 7751439 and a Short% of Float of 10.0.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
